TheProductLawyers.com announces new evidence disclosed in a recent article for Business Insider (BI). Bayer AG and the Johnson & Johnson subsidiary company, Janssen Pharmaceuticals, have lately been the subject of mounting litigation alleging a heightened risk of bleeding associated with their drug, Xarelto.
TheProductLawyers.com reports on some disconcerting news regarding IVC filters and the class action suits that have been filed against the makers of the device, specifically in Canada against Cook Medical.
TheProductLawyers.com reports on the surging controversy surrounding Duke University Clinical Trials for Xarelto, a new-generation blood-thinning drug manufactured by Janssen Pharmaceuticals, a Johnson and Johnson Corporation subsidiary, and Bayer AG.
In October of 2015, a new lawsuit was filed that veered from these standard accusations and focused instead on the ineffectiveness of the daily dosage requirement of Xarelto that did not take into account a patient’s size or weight.
A woman claims, that upon taking the type II diabetes drug, Invokana, she developed diabetic ketoacidosis. The complaint states that she began taking the drug in December of 2014 and developed ketoacidosis a short time after this.
TheProductLawyers.com reports on the scheduling of the first 4 bellwether Xarelto lawsuit cases that have been selected by Presiding Judge Eldon Fallon of the Eastern District of Louisiana who is the administrator of the current Multidistrict Litigation (MDL), identified as number 2592.
The Legal Examiner offers both bloggers and readers the opportunity to share their thoughts and opinions on all things law. From news on current legislative efforts to practical guidance on everyday legal issues, The Legal Examiner will have it covered. Learn More